Ionis Pharmaceuticals opened lower at $28.07, compared with its previous close of $28.33. In the last trading session, the stock traded between $27.28 and $28.56. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Ionis Pharmaceuticals is now worth
$ 81.36
Resulting in a loss of
$ 18.64 (18.64%)
Note: Past profits do not guarantee future returns.
Rating from 19 Analysts
Today's Change
$-1.03 (-3.62%)
Day High
$28.56
Day Low
$27.28
Day Open
$28.07
Prev Close
$28.33
Volume
46,01,355
1W Return
-31.97%
1M Return
-37.48%
3M Return
-50.71%
6M Return
-63.78%
1Y Return
-62.31%
Market Cap ($ Mn)
4,548
PE Ratio
-
PB Ratio
23.00
PEG Ratio
-
ROE
-68.04%
ROCE
-12.09%
EPS (TTM)
$-0.66
1 Week
-31.97%
1 Month
-37.48%
3 Months
-50.71%
6 Months
-63.78%
9 Months
-67.63%
Ionis Pharmaceuticals shares drop 24% on Tryngolza guidance cut
Ionis Pharmaceuticals shares fell over 24% after cutting Tryngolza 2026 sales guidance to ~$50 million from $100M-$110 million. Q3 revenue rose 55% YoY to $243 million, beating consensus estimates, while adjusted loss per share narrowed to $0.40. Levi & Korsinsky and Kehoe Law Firm are investigating potential securities law violations regarding misleading guidance statements. Tryngolza Q3 sales dropped to $9.3 million from $31.8 million in Q3 2025, signaling slower-than-expected sHTG market adoption.
TodayIonis DAWNZERA maintains 95% HAE attack reduction over two years
DAWNZERA showed 95% overall reduction in HAE attack rates in the OASISplus open-label extension cohort. Switch cohort patients experienced a 71% reduction in attack rates compared to prior therapy baselines. Treatment effect was maintained consistently across both every four and every eight week dosing schedules. No new safety signals were observed, with most adverse events being mild or moderate.
TodayOppenheimer maintains Outperform on Ionis, cuts price target to $70
Oppenheimer maintains an Outperform rating on Ionis Pharmaceuticals. Price target lowered from $85 to $70 by analyst Jay Olson.
2 days agoGoldman Sachs maintains neutral on Ionis, cuts price target to $41
Goldman Sachs maintained a Neutral rating on Ionis Pharmaceuticals. Price target lowered from $58 to $41 by analyst Salveen Richter. No change in investment stance despite reduced price objective.
2 days agoMorgan Stanley lowers Ionis price target to $75, keeps overweight
Morgan Stanley lowered Ionis Pharmaceuticals' price target from $104 to $75. The firm maintained an Overweight rating on the stock. Analyst Michael Ulz made the revision.
2 days agoRBC maintains Outperform on Ionis Pharmaceuticals, cuts price target to $60
RBC Capital maintains an Outperform rating on Ionis Pharmaceuticals. Price target lowered from $85 to $60 by analyst Luca Issi. The rating change reflects a revised valuation outlook for the company.
2 days ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Ionis Pharmaceuticals is now worth
$ 81.36
Resulting in a loss of
$ 18.64 (18.64%)
Note: Past profits do not guarantee future returns.
